Avenue Therapeutics, Inc. (ATXI)
OTCMKTS · Delayed Price · Currency is USD
0.3000
0.00 (0.00%)
Mar 31, 2025, 12:03 PM EST

Avenue Therapeutics Company Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases.

Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.

The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Avenue Therapeutics, Inc.
Avenue Therapeutics logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Alexandra MacLean

Contact Details

Address:
1111 Kane Concourse
Bay Harbor Islands, Delaware 33154
United States
Phone 781 652 4500
Website avenuetx.com

Stock Details

Ticker Symbol ATXI
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
ISIN Number US05360L3042
SIC Code 2834

Key Executives

Name Position
Dr. Alexandra MacLean M.D. Chief Executive Officer and Director
David Jin Interim Chief Financial Officer, Chief Operating Officer and Corporate Secretary
Dr. Lindsay Allan Rosenwald Executive Director
Dr. Scott A. Reines M.D., Ph.D. Interim Chief Medical Officer